Point72 Asset Management
MRVI icon

Point72 Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Point72 Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-100,000
Closed -$3.53M – 1546
2022
Q1 		$3.53M Buy
+100,000
New +$3.35M 0.01% 772

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
MAM
Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Point72 Asset Management's MRVI Position: Q1 2026 in Review

Point72 Asset Management increased its Maravai LifeSciences (MRVI) stake by 13% in Q1 2026, buying an estimated $1.21M and bringing the position to 3,205,496 shares worth $9.07M. The position accounts for 0.01% of the portfolio, ranked #1314.

Point72 Asset Management first reported a position in MRVI in Q4 2020 and has held it in 12 quarters since. The position peaked at $25.2M in Q2 2024. 158 funds tracked by Wall St. Rank hold MRVI as of Q1 2026.

  • Point72 Asset Management held 3,205,496 shares of Maravai LifeSciences worth $9.07M as of Q1 2026.
  • Point72 Asset Management bought 357,697 Maravai LifeSciences shares in Q1 2026, an estimated $1.21M.
  • Maravai LifeSciences made up 0.01% of Point72 Asset Management's portfolio in Q1 2026, its #1314 holding.
  • Point72 Asset Management first reported a position in Maravai LifeSciences in Q4 2020 and has held it in 12 quarters since.
  • Point72 Asset Management's Maravai LifeSciences position peaked at $25.2M in Q2 2024.
  • 158 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.